A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

A Phase 1, Double-Blind, Placebo-Controlled, Sponsor-Open, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-03654746 in Mild to Moderate Alzheimer's Disease Patients on Stable Donepezil Therapy

This is a study to evaluate the safety, tolerability and blood levels of PF-03654746 in subjects will mild to moderate Alzheimer's disease.

Inclusion Criteria:

• Probable Alzheimer's disease
• Mini Mental State Examination score 18-26 inclusive
• Aged 55-85

Exclusion Criteria:

• Dementia other than Alzheimer's disease
• Clinically significant cardiovascular disease in the past 6 months prior to screening
• Creatinine clearance <30 mL/min